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Characteristics, treatment, and control of
hypertension in public primary healthcare centers in
Nigeria: baseline results from the Hypertension
Treatment in Nigeria Program
Dike B. Ojji a,b, Abigail S. Baldridge c, Ikechukwu A. Orji a, Gabriel L. Shedul a, Tunde M. Ojo a,
Jiancheng Ye c, Aashima Chopra c, Boni M. Ale a, Grace Shedul a, Eugenia N. Ugwuneji a,
Nonye B. Egenti a,b, Kasarachi Aluka-Omitiran a, Rosemary C.B. Okoli d, Helen Eze a, Ada Nwankwo a,
Bolanle Banigbe e, Priya Tripathi c, Namratha R. Kandula c, Lisa R. Hirschhorn c, and
Mark D. Huffman c,f,g, on behalf of the Hypertension Treatment in Nigeria Program Investigators

Background: There are limited data on large-scale,
multilevel implementation research studies to improve
hypertension diagnosis, treatment, and control rates at the
primary healthcare (PHC) level in Africa. We describe the
characteristics, treatment, and control rates of patients
with hypertension in public PHC centers in the
Hypertension Treatment in Nigeria Program.
Methods: Data were collected from adults at least
18 years at 60 public PHC centers between January 2020
and November 2020. Hypertension treatment rates were
calculated at registration and upon completion of the
initial visit. Hypertension control rates were calculated
based on SBP and DBPs less than 140/90 mmHg.
Regression models were created to evaluate factors
associated with hypertension treatment and control status.
Results: Four thousand, nine hundred and twenty-seven
individuals [66.7% women, mean (SD) age ¼ 48.2 (12.9)
years] were included. Mean (SD) SBP was higher in men
compared with women [152.9 (20.0) mmHg versus 150.8
(21) mmHg, P ¼ 0.001]. Most (58.3%) patients were on
treatment at the time of registration, and by the end of
the baseline visit, 89.2% of patients were on treatment.
The baseline hypertension control rate was 13.1%, and
control was more common among patients who were
older [adjusted OR (95% CI) 1.01 [1.01 –1.02)], women
[adjusted OR (95% CI) 1.30 (1.05– 1.62)], who used fixed
dose combination therapy [adjusted OR (95% CI) 1.83
(1.49 –2.26)], and had higher education levels.
Conclusion: This baseline report of the largest facilitybased hypertension study in Africa demonstrates high
hypertension treatment rates but low control rates.
Keywords: global health, hypertension, implementation
research
Abbreviations: CI, confidence interval; HEARTS, Healthylifestyle counselling, Evidence-based treatment protocols,
Access to essential medicines and technology, Risk-based
CVD management, Team-based care, Systems for

monitoring; REDCap, Research Electronic Data Capture;
SD, standard deviation; STEPS, STEPwise approach to
Surveillance for noncommunicable diseases

INTRODUCTION

I

n low-income and middle-income countries, community-based studies demonstrate that less than 3 out of
every 10 patients are on treatment, and only 1 out of
every 10 patients have their blood pressure controlled [1]. In
Nigeria, which is the most populous country in Africa, the
most recent nationally representative data demonstrate an
age-standardized hypertension prevalence of 38%, with
suboptimal hypertension awareness (60%), treatment
(34%), and control (12%) rates [2]. Reasons for these low
rates are myriad and include: weak health systems, including lack of standardized protocols and health information
systems for longitudinal hypertension management; few
qualified, trained, and empowered health personnel to
provide team-based care; limited access to quality equipment and medicines; low health literacy; and direct and
indirect costs of evaluation and management [3–5].
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Evidence-based, multilevel implementation strategies to
improve hypertension treatment and control rates through
health behaviors and pharmacotherapy are recommended
to overcome multilevel barriers [6,7]. These strategies have
been demonstrated to improve hypertension control rates
from 44 to 90% in unselected patients in the Kaiser Permanente Northern California health system [8]. On the basis of
this evidence and experience, the WHO published its
HEARTS (Healthy-lifestyle counselling; Evidence-based
treatment protocols; Access to essential medicines and
technology; Risk-based CVD management; Team-based
care; Systems for monitoring) technical package in 2016
to improve cardiovascular care, including hypertension
care, by implementing these strategies at the primary
healthcare level [9].
However, despite the large burden of hypertension and
its consequences as well as the potential benefits of implementing evidence-based interventions, there are very limited number of reports of large-scale, multilevel
implementation research studies to improve hypertension
diagnosis, treatment, and control rates at the primary
healthcare level in Africa [9], and none in Nigeria. Furthermore, hypertension diagnostic and management services
have not been available in public, primary healthcare
settings in Nigeria, despite the perceived fit, acceptability,
appropriateness, relative advantage, and demonstrated feasibility. We, therefore, created the Hypertension Treatment
in Nigeria Program to implement and evaluate a culturally
and contextually adapted, large-scale, evidence-based
implementation package to improve the cascade of hypertension care in public, primary healthcare centers in the
Federal Capital Territory of Nigeria.
The primary objective of this baseline report was to
describe the clinical characteristics, treatment, and control
rates of patients with hypertension in public, primary health
centers in the Federal Capital Territory of Nigeria that are
part of the Hypertension Treatment in Nigeria Program.
Secondary objectives were to compare baseline rates of
blood pressure control by age, sex, level of education, area
council and to evaluate short-term retention, or follow-up
rates, in care during the baseline study period as recommended by Nigeria’s national hypertension treatment protocol [10].

METHODS
Study design and population
The Hypertension Treatment in Nigeria Program is a prospective, longitudinal type 2 hybrid implementation
research study that is evaluating implementation and effectiveness of a multilevel, evidence-based implementation
package using an interrupted time series design
(NCT04158154) [11]. Formative work, including site readiness assessment and sampling methods of primary healthcare centers, has been published [12]. Briefly, at the study
initiation, the Federal Capital Territory of Nigeria had 243
primary healthcare centers across 62 wards in 6 local
government area councils. To be eligible, study sites
needed to have two full-time staff and be operational,
accessible, and well tolerated for the research team to visit
and work. A multistage probability sampling frame was
Journal of Hypertension

used to select sites based on geographic representation and
population size, with additional sites selected after consultation with the Nigerian Federal Ministry of Health and the
Federal Capital Territory’s Primary Healthcare Board. All 60
selected primary healthcare centers agreed to participate
and were included in the program.
The first 11 months of the program (January 2020 to
November 2020) represented the preintervention, control
period, and the remaining 37 months represent the postintervention period (December 2020 to December 2023).
The multilevel implementation package was based on the
WHO HEARTS technical package [9] and Kaiser Permanente Northern California model [8] of hypertension control
and includes: patient registration and empanelment (health
system level), standard treatment protocol (national policy
level), encouragement of fixed-dose combination therapy
(health system level), team-based care (health worker
level), and home blood pressure monitoring and health
coaching (patient-level). During the control phase, the only
component of the implementation package used was a
registry for patient registration and empanelment. Prior
to initiation of the registry, physicians, nurses, community
health extension workers, and community health officers
received in-person, 2-day case-based training from the
research team on blood pressure measurement and principles of hypertension diagnosis and management based on
materials in the WHO HEARTS technical package [9]. Onsite training of the same staff as well as record information
officers preceded initiation at each site, which was indexed
by registration of the sites’ first patient with hypertension.
Initiation of all 60 primary healthcare centers occurred
between 20 January 2020 and 13 March 2020.

Study population
Sites were instructed to measure blood pressures among all
adults (18 years and older) who presented to the participating primary healthcare center using a standard approach.
Two blood pressure measurements were taken in each
patient by a trained physician, nurse, community health
extension worker, or community health officer using an
automated blood pressure monitor (Omron M3; HEM-7131E, Kyoto, Japan) provided by the study team. Blood pressures were measured after a 5 min rest period, and patients
were seated with their back, arms, and feet supported. The
research team performed periodic site monitoring and
supportive supervision to ensure that blood pressures were
measured accurately with additional, on-site training provided as needed.
Consecutive adults with hypertension, defined as: a
history of hypertension, persistently elevated SBP of
140 mmHg or above, persistently elevated DBP of 90 mmHg
or above, or use of blood pressure-lowering medications,
including those in the 2019 Nigeria Hypertension Treatment
Protocol [10], were registered at their respective primary
healthcare centers. Persistently elevated blood pressures
were defined based on two or more measurements taken at
least 1 week apart at respective health centers. Documentation of patient registration constituted addition to a sitebased ledger and inclusion of a paper case report form
within the patients’ file at the site. Registered patients were
given a diagnosis and treatment card and were asked to
www.jhypertension.com
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return to the primary healthcare center for monthly followup for usual care during the program’s baseline period.
Medical history, medications, and anthropometry data
were collected for each registered patient on paper case
report forms using a standardized protocol and methods by
trained study staff. Trained record information officers at
each study site performed electronic data entry using the
REDCap (Research Electronic Data Capture) mobile application hosted at the University of Abuja. REDCap is a
secure, web-based software platform designed to support
data capture for research studies, providing: an intuitive
interface for validated data capture; audit trails for tracking
data manipulation and export procedures; automated
export procedures for seamless data downloads to common statistical packages; and procedures for data integration and interoperability with external sources [13].
Staff from the 60 primary healthcare centers were provided with personal protective equipment and hand sanitizer by the study team at the beginning of the coronavirus
disease 2019 (COVID-19) pandemic in Nigeria to promote
healthcare worker and patient safety.

Statistical analysis
Bi-weekly data status and quality reports were created to
identify missing and low-quality data, including outliers
and data entry errors. The research team reviewed sites’
reports with respective record information officers to verify
or correct data based on review of source documents.
De-identified descriptive data were reported as means
(standard deviation) and medians (interquartile ranges,
IQR) for continuous variables if data were skewed, and
as proportions (95% CI) for categorical variables. Baseline
hypertension treatment rates were calculated by dividing
the number of patients taking one or more blood pressure
lowering medication at the time of first visit by the total
number of patients with hypertension. Treatment rates
using any (two-drug or three-drug) fixed-dose combination
were similarly calculated. Baseline hypertension control
rates were calculated by dividing the number of patients
with SBP and DBPs less than 140/90 mmHg by the total
number of patients with hypertension. The proportion of
treated patients who were controlled was also calculated.
Data were analyzed overall and by key subgroups, including by sex, primary healthcare center, area council, and
calendar month. We calculated the rate of retention, or
follow-up rate, based on return to clinic within 31 days of
the baseline visit. We also calculated follow-up at 37 days as
a sensitivity analysis. Follow-up clinical data will be
reported in future reports.
A complete case analysis was performed. Hierarchical
mixed-effect multivariable logistic regression models were
created to evaluate associations between patient, site, and
area council-level factors and baseline hypertension treatment and control. Unadjusted and adjusted models are
reported. Models were adjusted for age, sex, and patients’
level of education as a marker of socioeconomic position as
well as factors previously demonstrated to be associated
with hypertension awareness (as a proxy for health system
access), baseline treatment (i.e. fixed dose combination
therapy), and blood pressure as a proxy for baseline control
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(i.e. BMI, alcohol use) [1,2]. Random effects modeling
was used to account for within-site clustering. A two-sided
P value less than 0.05 was used to detect statistical significance, and no adjustments were made for multiple comparisons. SAS version 9.4 (SAS, Cary, North Carolina, USA)
and R version 4.0.5 (R Foundation, Vienna, Austria) were
used for statistical analyses.

Ethics review and informed consent
The study protocol was reviewed and approved by the
ethics boards of University of Abuja Teaching Hospital,
Federal Capital Territory of Nigeria, and Northwestern
University, as well as the program’s Data and Safety Monitoring Board. Patient informed consent was waived based
on the Common Rule.

RESULTS
Study population
From January 2020 to November 2020, 5103 unique patients
were recruited and registered from 60 primary healthcare
centers in six area councils. After excluding individuals with
missing or erroneous data on age, sex, or blood pressure or
without meeting diagnostic criteria for hypertension, there
were 4927 individuals included in the current analysis
(Fig. 1) and who had 13 256 unique visits (Supplemental
Table 1, http://links.lww.com/HJH/B857). The median
(IQR) number of registered patients at each primary health
center per month was 7 (Supplemental Fig. 1, http://links.
lww.com/HJH/B856).
Table 1 reports patients’ demographics and clinical characteristics, overall and by sex. Mean (standard deviation,
SD) age was 48.2 (12.9) years, 66.7% were women, and
27.2% never attended school. Most (56.2%) patients had a
prior history of hypertension but self-reported history of
comorbid factors was uncommon, including diabetes mellitus(5.9%), stroke,(1.1%), heart attack (0.4%), and heart
failure (0.4%). Smoking was reported in 1.3% of patients,
with a higher smoking rate in males compared with women
(3.3 versus 0.3%, P < 0.001). Mean (SD) BMI washigherinwomencomparedwithmen[27.8(6.2)kg/m2 versus 26.2
(4.9) kg/m2, P < 0.001]. The mean (SD) of the second
SBP measured was higher in men compared with women
[152.9 (20) mmHg versus 150.8 (21) mmHg, P ¼ 0.001], but
mean DBP levels were similar between men and women.
Table 2 outlines blood pressure medication type and
class at the time of registration, during the baseline visit, and
at the end of the baseline visit. More than half (58.3%) of
patients were on treatment at the time of registration with
single dose, or free pill, medications (57.3%) being the most
used drug type among treated patients, compared with twodrug (35.7%) and three-drug (7.0%) fixed dose combinations. Calcium channel blockers (82.7%) were the most
used drug class at the time of registration, followed by
diuretics (25.3%) and angiotensin-converting enzyme
inhibitors (19.4%). During the baseline visit, 2876 (58.4%)
patients received a renewed or newly prescribed medication, which was most commonly a calcium channel blocker
(83.8%). By the end of the baseline visit, 4395 (89.2%)
patients were on treatment, and the median (interquartile
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FIGURE 1 Flow diagram of study participants.

range) number of blood pressure-lowering medications
prescribed per patient was 1 [1–2].
Figure 2 demonstrates the treatment and control rates
with corresponding 95% CI by sex from January 2020 to
November 2020 with proportions reported in Supplemental
Table 2, http://links.lww.com/HJH/B857. Overall, treatment rates at the baseline visit modestly increased over
the baseline period, reaching 94% (95% CI 91–98%) in men
and 93% (95% CI 90–95%) in women (P ¼ 0.40 for between
sex group differences; Ptrend <0.001 for both sex groups).
Over the same time, control rates at the baseline visit
declined modestly, reaching 8% (95% CI 4–11%) in men
and 9% (95% CI 6–13%) in women (P ¼ 0.46 for between
sex group differences; Ptrend < 0.001 for both sex groups).
Females had a higher overall control rate at the baseline
visit compared with men [14% (95% CI 13–15%) versus 11%
(95% CI 10–13%)].
Sex-stratified treatment and control rates at the baseline visit by area council are shown in Supplemental
Table 3, http://links.lww.com/HJH/B857. Treatment and
control rates by area council were more variable among
women than among men. Women in Kwali had the
highest treatment rate (95%, 95% CI 93–97%), and
Journal of Hypertension

women in Gwagwalada had the lowest treatment rate
(84%, 95% CI 81–87%). On the other hand, women in
Abaji had the highest control rate (30%, 95% CI 26–34%),
and men in Bwari had the lowest control rate (4%, 95%
CI 1–6%).
The cascade of hypertension care is reported in Fig. 3.
All patients with hypertension, whether they had been
previously diagnosed or undiagnosed, are represented as
100%. From this total, 58.3% had been treated prior to the
start of the baseline visit, and 13.1% had controlled hypertension at their baseline visit. Among those who were
treated prior to the start of the baseline visit, the control
rate was 19.2%. Monthly treatment and control rates varied
substantially by primary healthcare center, which are
shown in Supplemental Figs. 3 and 4, respectively,
http://links.lww.com/HJH/B856. Supplemental Table 4,
http://links.lww.com/HJH/B857 demonstrates the logistic
regression results. After multivariable adjustment, older
patients were more likely to have their hypertension
treated [adjusted odds ratio, OR (95% CI) 1.02 (1.01–
1.03) per year], as were individuals with some education
compared with never having attended school. Hypertension control was more common among individuals who
www.jhypertension.com
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TABLE 1. Patients’ baseline sociodemographics, clinical characteristics, and blood pressure overall and by sex
Variables
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Age, mean (SD) (years)
Pregnant [no. (%)]
BMI, mean (SD) (kg/m2)
Education [no. (%)]
Never attended school
Primary school
Secondary school
High school
College/university
Professional degree
Othera
History of hypertension [no. (%)]
History of diabetes [no. (%)]
History of heart failure [no. (%)]
History of chronic kidney disease [no. (%)]
History of stroke [no. (%)]
History of heart attack [no. (%)]
Current smoker [no. (%)]
Former smoker [no. (%)]
Current alcohol user [no. (%)]
Former alcohol user [no. (%)]
First SBP [mean (SD), mmHg]
Second SBP [mean (SD)] (mmHg)
First DBP [mean (SD)] (mmHg)
Second DBP [mean (SD)] (mmHg)
Heart rate [mean (SD)] (bpm)

Total (N ¼ 4927)

Male (N ¼ 1642)

Female (N ¼ 3285)

P value

48.2 (12.9)

51.5 (12.3)
–
26.2 (4.9)

46.6 (12.8)
75 (2.3)
27.8 (6.2)

<0.001
NE
<0.001
<0.001

27.3 (5.9)
1338
952
1198
193
1030
146
56
2767
292
18
14
56
19
51
63
216
112
156.8
151.5
96.7
94.7
84.0

(27.2)
(19.4)
(24.4)
(3.9)
(21.0)
(3.0)
(1.1)
(56.2)
(5.9)
(0.4)
(0.3)
(1.1)
(0.4)
(1.0)
(1.3)
(4.4)
(2.3)
(21.1)
(20.8)
(14.1)
(14.0)
(17.8)

287
287
395
88
478
73
30
895
96
3
6
31
8
39
54
154
72
157.8
152.9
96.4
94.4
82.4

(17.5)
(17.5)
(24.1)
(5.4)
(29.2)
(4.5)
(1.8)
(54.9)
(5.9)
(0.2)
(0.4)
(1.9)
(0.5)
(2.4)
(3.3)
(9.4)
(4.4)
(20.7)
(20.0)
(14.1)
(13.8)
(14.1)

1051
665
803
105
552
73
26
1872
196
15
8
25
11
12
9
62
40
156.4
150.8
96.8
94.9
84.8

(32.1)
(20.3)
(24.5)
(3.2)
(16.9)
(2.2)
(0.8)
(57.7)
(6.0)
(0.5)
(0.2)
(0.8)
(0.3)
(0.4)
(0.3)
(1.9)
(1.2)
(21.3)
(21.0)
(14.2)
(14.0)
(19.3)

0.07
0.51
0.19
0.64
0.003
0.49
<0.001
<0.001
<0.001
<0.001
0.07
0.001
0.20
0.11
<0.001

NE, nonestimable; SD, standard deviation.
a
Including Arabic school, Islamic school, Bible school, or technical/vocational school.

were older [adjusted OR (95% CI) 1.014 (1.01–1.02)], were
female [adjusted OR (95% CI) 1.30 (1.05–1.62)], used fixed
dose combination therapy (adjusted OR (95% CI): 1.83
(1.49–2.26)], and had high school education and above.
Patients in Abuja Municipal Area Council [adjusted OR
(95% CI) 0.41 (0.18–0.92)], Bwari [adjusted OR (95% CI)

0.24 (0.09–0.64)], and Kwali [adjusted OR (95% CI) 0.13
(0.05 –0.38)] had lower odds of hypertension control
compared with Abaji.
Supplemental Figures 2a and 2b, http://links.lww.
com/HJH/B856 show the mean retention rates at 31
and 37days, respectively, by primary healthcare center.

TABLE 2. Number, type, and class of blood pressure-lowering medication at the time of registration, during the baseline visit, and at the
end of the baseline visit
Blood-pressure lowering medications
at baseline
Number of medications per person [median (IQR)]
Any medication [no. (%)]
Type of blood pressure lowering medicationa,b
Single dose (free pill) medication [no. (%)]
Fixed dose combination with two medications [no. (%)]
Fixed dose combination with three medications [no. (%)]
Class of blood pressure lowering medicationb
Angiotensin-converting enzyme inhibitor [no. (%)]
Angiotensin receptor blocker [no. (%)]
Beta blocker [no. (%)]
Calcium channel blocker [no. (%)]
Central acting agent [no. (%)]
Diureticc [no. (%)]
Vasodilator [no. (%)]
Undefinedd [no. (%)]

At the time of
registration
(N ¼ 4927)

Prescribed during
baseline visit
(N ¼ 4927)

Medications at
end of baseline
visit (N ¼ 4927)

1 (0–2)
2871 (58.3)

1 (0–1)
2876 (58.4)

1 (1–2)
4395 (89.2)

1644 (57.3)
1025 (35.7)
202 (7.0)

1921 (66.8)
800 (27.8)
155 (5.4)

2503 (57.0)
1565 (35.6)
327 (7.4)

558
367
18
2374
346
727
21
8

296
602
8
2410
169
275
3
4

769
803
24
3881
454
918
22
10

(19.4)
(12.8)
(0.6)
(82.7)
(12.1)
(25.3)
(0.7)
(0.3)

(10.3)
(20.9)
(0.3)
(83.8)
(5.9)
(9.6)
(0.1)
(0.1)

(17.5)
(18.3)
(0.5)
(88.3)
(10.3)
(20.9)
(0.5)
(0.2)

a
Type of medication is based on most complex type of medication taken. If the patient is on both a fixed dose medication with two agents, and a single dose medication, then they are
reported here in the fixed dose with two medications row.
b
Some patients are prescribed multiple drugs or fixed dose medications, so the column percentages may add to more than 100%.
c
Including furosemide, spironolactone, thiazide, or other diuretic.
d
Drug name or class were unspecified.
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FIGURE 2 Treatment and control rate (95% confidence interval) at patients’ baseline visit by calendar month.

The mean 31-day retention rate was 25% (95% CI 20–
31%), and the mean 37-day retention rate was 39%
(95% CI 32–45%) with wide variability among sites.

DISCUSSSION
Summary of results
This report represents the largest facility-based study of
hypertension care in Nigeria and in sub-Saharan Africa,
demonstrating the cascade of hypertension care from 60
public, primary healthcare centers in the Federal Capital
Territory. Patients in this registry had relatively low levels of
education and low self-reported rates of smoking and
comorbid diseases. At the time of patient registration, rates
of hypertension treatment and control were 58.3 and 13.1%,
respectively. The hypertension treatment rate increased to
89.2% at the end of the study baseline visit, which can be

likely attributed to the influence of registration, health
worker training, and study participation. There was wide
variability across primary healthcare centers in terms of
number of patients recruited and hypertension treatment
and control rates with higher rates among patients who
were older, women, and with higher levels of education.
Hypertension control was more common among individuals who used fixed-dose combination therapy but was less
common in Abuja Municipal Area Council, Bwari, and
Kwali compared with Abaji.
Baseline treatment rates at the time of registration
increased over the study period, which may have resulted
from a combination of sites’ study participation, including
health worker training, temporal trends, and the Hawthorne effect. Monotherapy with calcium channel blockers
or angiotensin receptor blockers were the most frequently
newly prescribed blood pressure-lowering medications in

FIGURE 3 Hypertension cascade of care for baseline visits. The walk-in treatment rate can be considered the rate at the start of a patient’s baseline visit.
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accordance with the 2019 national hypertension protocol
[10]. Retention rates were 25 and 39% at 31 and
37 days, respectively.

Results in context
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The baseline hypertension treatment rate (58.3%) in the
current study was higher than previous community-based
reports in Nigeria and other low-income and middleincome countries, including in countries in Africa
[1,2,14]. Differences in treatment can be likely attributed
to differences in sampling between facility-based and community-based studies and corresponding health-seeking
behavior, as well as availability of hypertension services
at the primary healthcare level. In addition, these may also
be partly attributed to the Nigeria Hypertension Control
Initiative, which was announced by the Federal Ministry of
Health, WHO Nigeria, and Resolve to Save Lives in August
2019 [15] with publication of a national hypertension treatment protocol in June 2020 [10]. Nevertheless, the reported
hypertension control rate (13.1%) is comparable to and
complements the latest national, community-based estimate in Nigeria (12%), albeit with variation among area
councils [2]. Follow-up hypertension control rates may be
higher than baseline, given the relatively high rate of blood
pressure-lowering treatment prescribed during the registration visit and time needed for these medications to take full
effect, even with variable medication adherence rates. The
Federal Ministry of Health and WHO Nigeria plan to collect
demographic health surveillance data for noncommunicable diseases in the second half of 2021 using the WHO
STEPwise approach to Surveillance for noncommunicable
diseases (STEPS), which will further complement these
results.
The higher recruitment and hypertension control rates of
female participants in hypertension studies in Africa has
been shown in large population hypertension registries in
Africa [16,17]. Potential reasons for these differences
between sexes include earlier detection of hypertension
in women at both antenatal and postnatal cares, and higher
health-seeking behaviors in African women compared with
men. Similar to the current study results, previous research
has demonstrated that individuals who are older, women,
and with higher education were more likely to have hypertension treated and controlled in other low-income and
middle-income countries [1,2]. Fixed-dose combination
therapy has been also demonstrated to increase hypertension control [18].
Both the current study and aforementioned reports use
point prevalence estimates, which may overestimate the
true hypertension control rate. The WHO HEARTS technical
package recommends using a 6-month hypertension control rate, which is generally considered to be a more
rigorous and reliable method and will be incorporated in
future analyses. However, although this method may more
accurately estimate sustained hypertension control,
patients need to be retained in care to calculate these
estimates. In the current study, less than 40% of patients
were retained in care at 37 days. Thus, defining hypertension control over 6 months may similarly overestimate the
true rate of hypertension control in a health facility’s
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catchment area because of a healthy user bias [19]. Nevertheless, among 18 countries that have implemented the
WHO HEARTS technical package, 6-month hypertension
control rates ranged from 18% (Dominican Republic) to
79% (Ecuador) [5]. Ethiopia was the only African country
that has reported results in this program and showed a
higher hypertension control rate (42%). Nigeria also participates in this program through Kano and Ogun states but
has not reported results to date.
In addition to multilevel implementation strategies to
improve the cascade of care [5], strategies will need to be
contextualized and implemented to improve coverage and
retention across sociodemographic groups that were less
likely to be represented in the current study, including
patients who are younger, male, and with less education.
Lower baseline treatment rates at the time of registration
among some of these groups suggest that availability of
services at the primary healthcare level may help to address
these coverage gaps.
Specific treatment strategies may also be effective at
improving treatment coverage. Further, the Nigeria national
hypertension treatment protocol encourages the early use
of two-drug and three-drug fixed-dose combination therapy based on high-quality evidence demonstrating greater
effectiveness and efficiency with similar tolerability compared with monotherapy [18,20]. However, despite fixeddose combination blood pressure-lowering therapy being
listed on the WHO Model List of Essential Medicines [21],
fixed-dose combination use in the current study was used in
the minority of patients at baseline (38.4%) and was infrequently available (7%) among primary healthcare centers in
the Federal Capital Territory prior to study initiation [13]. To
address this gap, the study team embedded a cluster randomized trial within the Hypertension Treatment in Nigeria
Program in January 2021 to evaluate the effect of a strategy
that uses initial fixed-dose combination therapy compared
with monotherapy (NCT04158154).

Strengths and limitations
This study has several strengths, including using a prospective study design, recruitment of a large sample of patients
from 60 public, primary healthcare centers, training and
retraining of PHC staff, and rigorous data monitoring and
analysis. The study also safely recruited patients and collected high-quality data from settings that had not previously conducted research and during the COVID-19
pandemic, demonstrating the feasibility of research in challenging conditions. On the other hand, this study also had
limitations. First, the study setting was in one state in
Nigeria; thus, these results may not necessarily be generalizable to other states in Nigeria. However, the study team
collaborates with researchers and stakeholders in Kano and
Ogun states to harmonize study procedures, including the
same national treatment protocol [10], which will allow for
comparisons among different regions in Nigeria. Second,
although the trained study staff were instructed to measure
blood pressure on every patient who came to the primary
healthcare center, it is possible that some patients’ blood
pressures were not measured. Nevertheless, the study team
performed regular site-level monitoring and supportive
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supervision visits to directly observe study procedures,
including registration and blood pressure measurement,
with real-time feedback to maximize adherence to study
procedures. Third, treatment and control rates only represent data from patients’ baseline visits and may differ over
time. Longitudinal analyses will be an area of future study
within this program. Fourth, despite efforts to optimize data
quality, including bi-weekly data status and quality reporting, there were some missing or low-quality data that
needed to be excluded, even after source document review.
However, the proportion of patients excluded was small
(3.4%), and thus not likely to influence the validity of this
report. Fifth, we did not collect self-reported measures of
medication adherence, which have limitations related to
recall and social desirability bias. Longitudinal measures of
blood pressure, and subsequent hypertension control rates,
provides an objective and feasible method for monitoring
adherence compared with other approaches, such as pill
counts and pharmacy data.
In conclusion, the current report describes the largest
facility-based study of the hypertension cascade of care
in Nigeria and in Africa. This report serves as the
baseline for a prospective, longitudinal type 2 hybrid
implementation study that tests the effectiveness and
implementation of a multilevel, evidence-based implementation package using an interrupted time series
design. Contextualization, implementation, sustainment,
and spread of evidence-based strategies for better hypertension treatment and control at the primary healthcare
level are needed to reduce the burden of cardiovascular
diseases in Nigeria.
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